What happened

Shares of MediciNova, Inc. (NASDAQ:MNOV), a clinical-stage biopharmaceutical company, are down around 13.2% as of 12:11 p.m. EST on Thursday. The company recently pleased investors with positive data for its lead candidate, but investors aren't happy with how the company will go about funding a pivotal trial with ibudilast for the treatment of progressive multiple sclerosis (MS).

So what 

After the bell yesterday, MediciNova, Inc. announced it would offer around 5 million shares for just $9.05 each, which was well below the market price at the time. The stock surged above $11 earlier this month after the company presented data showing ibudilast, the molecule formerly known as MN-166, led to a 26% disability progression reduction for patients with progressive MS.

Person making a frustrated gesture while looking at stock charts.

Image source: Getty Images.

While the data warrants further investment into a larger pivotal trial, the offering will raise MediciNova's outstanding share count about 14% higher. The dilutive effects of the secondary offering will significantly reduce investors' slice of any profits MediciNova might earn down the road, but will only add around $46 million to the company's cash pile.

Now what

MediciNova had just $24.5 million in cash and equivalents on the books when the company last reported. To address concerns that the company's balance sheet is too modest to fund a proper pivotal study the nine-employee company thinks it can satisfy regulators with a relatively small, 700-patient pivotal trial. 

MediciNova wants to use the same disability progression metric ibudilast scored high on during its mid-stage progressive MS study as the primary endpoint for an upcoming pivotal trial. Investors will want to look for signs the FDA is on the same page. Small biotechs have a dangerous tendency to ignore the agency's advice when it doesn't jive with the soothing narratives they present investors.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.